An historical review of systemic lupus erythematosus in Latin America

Medical Science Monitor

Volumn 10, Issue 7, 2004, Pages

  Gamarra, Antonio Iglesias ^a   Matteson, Eric L ^b,e   Rodriquez, Antonio Iglesias ^c   Rodriguez, Melissa Iglesias ^d   Suarez, Jose Felix Restrepo ^a  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF CHILE   (Chile)

^e Mayo Clinic   (United States)

Author keywords

History; Latin America; Systemic lupus erythematosus

Indexed keywords

ALCOHOL; ANTIMONY; ARSENIC; BARIUM CHLORIDE; BISMUTH; CALCIUM CHLORIDE; CHLORMETHINE; COD LIVER OIL; CORTICOSTEROID; CORTICOTROPIN; CORTISONE; GLUCOCORTICOID; GOLD SALT; IODIDE; IRON; IRON DERIVATIVE; LIVER EXTRACT; MERCURY DERIVATIVE; NICOTINAMIDE; NICOTINIC ACID; PENICILLIN G; PHENOL; POTASSIUM; QUININE; STEROID; SULFONAMIDE; SURAMIN; UNINDEXED DRUG; VITAMIN K GROUP; WATER;

ELECTRON MICROSCOPY; HEALTH CARE ORGANIZATION; HISTORY; HUMAN; MEDICAL RESEARCH; MICROSCOPY; PALEOPATHOLOGY; PATHOGENESIS; RADIOGRAPHY; REVIEW; SOUTH AND CENTRAL AMERICA; SYSTEMIC LUPUS ERYTHEMATOSUS;

CLINICAL TRIALS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LATIN AMERICA; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 3342953807     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (151)

1. Gedding WH: On lupus erythematosus Am J Med Sci. 1869; 58: 58-59
2. Kaposi M" Neue Beiträge zur " Kenntnis des lupus erythematosus. Arch Dermatol Syph, 1872; 4: 36-79
3. Allison MJ, Gersztein E, Martínez AJ et al: Generalized connective tissue disease in a mummy from Huari culture (Perú). Bull New York Acad Med, 1977; 53(3): 292-301
4. Aguilar MC: Sobre la naturaleza y tratamiento del lupus no diatésico, Tesis Inaugural, 1885
5. Martínez Osuna P: La reumatología en México. Siglo XIX. Revista Mex Reumatol. 1994; 9: 139-42
6. Carvallo Elizalde V: Revista Extranjera. Tratamiento del Lupus Rev Med Chile, 1880; 8: 299-302
7. Sierra Mendoza L: Hospital de San Vicente de Paúl: Servicio del Profesor Barros Borgoño. Rev. Med Chile, 1890; 18: 670-73
8. Dávila Boza R: Revista Extranjera. Tratamiento del lupus. Rev Med Chile, 1892; 20: 527-34
9. Zegers PR: Revista Extranjera. Tratamiento del lupus por el doctor R. Dávila Boza. Rev Med Chile, 1893; 21: 63-73
10. Seminario C, Pessano J: Cuatro casos clínicos de lupus eritematoso agudo. Sem Med (Buenos Aires), 1930; 2: 721-28
11. Manifestations of systemic lupus erythematosus. JAMA, 1974; 227: 1399-402
12. Valenzuela Ravest F: Reumatología, Reumáticos y Reumatólogos. Rev Med Chile, 1985; 113: 65-73
13. Armas Cruz R, Harnecker J: "Lupus eritematoso generalizado" Rev Med de Chile, 1950; 78(Suppl 1): 1-35
14. Armas Cruz R, Harnecker J, Parrochia E: Cortisona en el lupus eritematosos generalizado. Rev Med de Chile, 1952; 80: 449
15. Armas Cruz R, Harnecker J, Parrochia E: Generalized lupus erythematosus. Semaine hôp Paris, 1954; 30: 73-90
16. Armas Cruz R, Harnecker J: Veinticinco casos de lupus eritematoso gene-ralizado tratados con cortisona. Revista Médica de Chile, 1953; 323-31
17. Zañartu J, Medina E: Experiencia con Hormona adrenocorticotrófica. (ACTH) y cortisona: I En lupus eritematoso diseminado. Rev Med Chile, 1951; 79: 6-13
18. Dubois E, Commons RR, Stare P et al: Corticotropin and cortisone treatment for systemic lupus erythematosus. JAMA, 1952; 149: 995-1001
19. Brunsting L, Slocumb CH, Didcot J: Effects of cortisone on acute disseminated lupus erythematosus. Arch Dermat Syph, 1951; 63: 29-35
20. Zañartu J, Losada M: El uso de cortisona y ACTH (corticotrofina) en el tratamiento de las enfermedades del mesénquima. Rev Med Chile, 1953; 332-41
21. Armas Cruz R, Harnecker J: Experienzed with 50 cases of generalized lupus erythematosus. Rev Med Chile, 1954; 82: 1
22. Plaza de los Reyes M, Monsalve J, Antillo A: Dos casos de lupus eritematoso generalizado tratados con mostaza nitrogenada. Revista Med de Chile, 1952; 176-178
23. Mazzini MA, Momam, García S: Mostaza nitrogenada en dermatología, Prensa Med Argentina, 1954; 41: 1737
24. Dubois EL: Nitrogen mustard in treatment of systemic lupus erythematosus. Arch Inter Med, 1954; 667-72
25. Gómez EL: Manifestaçoes viscerais do eritematodes maligno. Revisáo da literatura e apresentacdo de 6 casos com studo anatomo patológico. Arch Brasil Med, 1952; 42: 5
26. Mazzei ES, Dameno E: El eritematodes maligno. Pren Méd Argent, 1952; 39: 1850
27. Benain Pinto H: Lupus eritematoso agudo diseminado, con tuberculosis ganglionar y probable enfermedad de Addison. Acta Med Venez, 1953; 7: 303
28. Baptista L, Belliboni N: Eritematodes diseminado Arch Argent Dermat, 1954; 4: 1
29. Dameno E. El eritematodes maligno. Presna Med Argent, 1958; 45-60
30. Sánchez Caballero HJ: Sobre la unidad nosológica del lupus eritematoso y las posibilidades evolutivas de la forma fija. Sem Méd (Buenos Aires), 1954; 104: 432
31. Iglesias Gamarra A, Peña Cortés M, Restrepo JF: Historia de la Reumatología Colombiana, 1999; 6: 358-406
32. Ambrosetti F, Corti RN: Las colagenosis en dermatología. Día Med, 1956; 28: 1756
33. León A, Lamberti J, Figuera A: Lupus Eritematoso diseminado. Acta Med Venez, 1957; 5: 43
34. Mosquera JM: Estudio Clínico oftalmoscópico del lupus eritematoso sistémico. Sem Méd (Buenos Aires), 1958; 112: 781
35. Astorga G: Un caso de lupus eritematoso diseminado con hemiplejia. Rev Med Chile, 1959; 87: 204
36. Benito AS, Almaraz QC: Contribución al estudio de las alteraciones neuropsíquicas del lupus eritematoso diseminado Rev Clin Esp, 1958; 70: 312
37. Castillo PA, López Fernández F, Pons Martínez I: La prueba de precipitación de Jones y Thompson en el lupus eritematoso sistémico. Rev Cubana Lab Clin, 1959; 13: 12
38. Actis CA, Rubinstein A: Lupus eritematoso agudo diseminado en pediatría. Prensa Med Arg, 1959; 46: 1232
39. Molina VI, Toro Mejía A: Lupus eritiematoso diseminado. Antioquia Médica, 1959; 9: 89-126
40. Giussani RM, Tapella PA, Ursi A, Babriskis IA: Lupus eritematoso sistémico familiar. Prensa Med Arg, 1960; 47: 2127
41. Poch GF: Enfermedades del colágeno. Manifestaciones neurológicas musculares y psiquiátricas. López Libreros Editores SRL, Buenos Aires, 1960; 95-98
42. Pineda Vásquez Pablo: Lupus eritematoso sistematizado. Editorial Cuyuní. Barquisimeto, 1977
43. Armas Cruz R, Harnecker J, Ducah G et al: Clinical diagnosis of systemic lupus erythematosus. Am J Med, 1958; 25: 409-19
44. Massardo L, Jacobelli S: The Chilean experience of systemic lupus erythematosus. Lupus, 1996; 5: 178-77
45. Jalil J, Armas Cruz R, Harnecker J, González F: Lupus eritematoso generalizado. Análisis de 100 casos tratados con corticoides suprarrenales y comparación con 25 casos no tratados. Rev Med Chile, 1959; 86: 717-32
46. Losada M, Awad T, Donoso S: Correlación clínico anatómica en el lupus eritematoso generalizado. Rev Med Chile, 1970; 98: 586-91
47. Rosenberg H, Jacobelli S, Vaccarezza A, Sorensen R: Nefropatía lúpica. Correlación clínico morfológica. Rev Med Chile, 1976; 104: 425-32
48. Jacobelli S, Massardo L, Rodríguez G et al: Análisis de la sobrevida en enfermos con lupus eritematoso generalizado. I. Rev Med Chile, 1985; 113: 744-50
49. Massardo L, Martínez ME, Jacobelli S et al: Survival of Chilean patients with systemic lupus erythematosus. Semin Arthritis Rheum, 1994; 24: 1-11
50. González B, Elgueta S, Talesnik E et al: Lupus eritematoso diseminado en la infancia. Estudio clínico y de sobrevida en 31 casos. Rev Chil Ped, 1984; 55: 238-44
51. Jacobelli S, Moreno R, Massardo L et al: Inspiratory muscle dysfunction and unexplained dyspnea in systemic lupus erythematosus. Arthritis Rheum, 1985; 28: 781-88
52. Carvallo A, Moreno E: Lupus eritematoso sistémico y embarazo. Experiencia clínica en 57 pacientes. Rev Med Chile, 1989; 117: 1243-50
53. Abumohor P, Cerda C, Neira O et al: Anticuerpos anticardilipinas en el lupus eritematoso sistémico: prevalencia y asociaciones clínicas. Rev Med Chile, 1991; 119: 517-23
54. Rivero SS, Llorente L, Díaz Jovanen E, Alarcón Segovia D: T Lymphocyte subpopulation in untreated SLE. Variation with disease activity. Arthritis Rheum 1977; 20: 1169-73
55. Pincheira R, Bull P, Massardo L et al: Increased levels of the protooncogen c-rel mRNA in patients with either active or inactive systemic lupus erythematosus. Lupus, 1995; 4(S2): 84, (abstract)
56. Gutiérrez MA, Molina JE Jara LJ et al: Prolactin induced immunuclear cells from systemc lupus erythematosus and normal individual. Int Arch Allergy Immunol, 1996; 109: 229-35
57. Patrucco R, Silicani A: Lupus eritematoso diseminado. Estudio clínico inmunológico. Tribuna Médica, 1968; 48: 32-34
58. Jara LJ, Lavalle C, Fraga A et al: Prolactin immunoregulation, and autoimmune diseases. Sem Arthritis Rheum, 1991; 20: 273-84
59. Alarcón GS, Calderón JL: Sensitivy and specificity of the American Rheumatism Association criteria for the diagnosis of systemic lupus erythematosus. Acta Med Per, 1975; 4: 35
60. Castañeda O, Alarcón GS, González del Riego M, Situ O: Systemic lupus erythematosus and pregnancy. Acta Med Per, 1980; 7: 53-56
61. Alarcón GS, Roseman J, Bartolucci AA et al for the lumina study group: Systemic lupus erythematosus in three ethnic groups. Arthritis Rheum, 1998; 41: 1173-80
62. Alarcón GS, McGwin G Jr, Bastian HM et al: Systemic lupus erythematosus in three ethnic groups. VIII. Predictors of early mortality in the lumina cohort. Arthritis Care Research, 2001; 45: 191-92
63. Orellana Meléndez E: Determinación de morbimortalidad de pacientes con lupus eritematoso sistémico en Guatemala. Universidad Francisco Marroquín. Facultad de Medicina Guatemala, junio de 1989
64. Samayoa EA, Cáceres J, Beber R, Montenegro P: Lupus eritematoso sistémico, experiencia con 181 pacientes. Sección de Reumatología Hospital General San Juan de Dios, enero de 1994
65. Patarroyo ME, Chalem F, Alvarado H: Lupus eritematoso sistémico: Clases y subclases de anticuerpos antinucleares y su relación con la actividad antigamaglobulina. Acta Méd Colomb, 1977; 2(4): 223-39
66. Caraballo García LR, García M LF, Molina J, Medina ME: Poblaciones de linfocitos y anticuerpos linfocitotóxicos. Tribuna Médica, 1979; 59: 37-43
67. Statsny P, Zif M: Antibodies against cell membrane constituients in SLE and related diseases. I cytotoxic effects of serum of patients with lupus erythematosus for alogenic and for autologous lymphocytes. Clin Exp Immunol, 1971; 8: 543-41
68. Mittal KK, Rossen RD, Sharp JT et al: Lymphocitotoxic antibodies in systemic lupus erythematosus. Nature, 1970; 225: 1255-69
69. Molina J, Dubois EL, Bilitch M et al: Procainamide Induced serologic changes in Asymptomatic patients. Arthritis Rheum, 1969; 12: 608-13
70. Agudelo CA, Schumacher HR, Glick JH, Molina J: Non Hodgkin's Lymphoma in systemic lupus erythematosus. Report of 4 cases with ultrastructural studies in 2.J Rheumatol, 1981; 8: 69-78
71. Cammarata HJ, Rodnan GP, Jensen WN: Systemic rheumatic disease and malignant lymphoma Arch Intern Med, 1963; 111: 330-37
72. Valle RR, Eaton R, Schnneider G, Schur P: Complement activation by antibodies to DNA in systemic lupus erythematosus measured by enzyme immunoassay. Clin Immunol Immunopathology, 1985; 34: 345-54
73. Fronek Z, Valle RR, Eaton RB, Schur PH: The relationship between Sm and Rnp antigens. Clinical Immunology Immunopathology, 1986; 41: 91-107
74. Núñez DC, Ruiz CY, Barrera N et al: Prevalencia de anticuerpos antinucleares en un grupo de adultos sanos residentes en Santafé de Bogotá. Acta Med Colombiana, 1995; 20: 163-68
75. Restrepo JF, Guevara S, Peña M, Lizarazo H: Lupus eritematoso sistémico. Características clínicas serológicas de 106 pacientes. Acta Med Colombiana, 1992; 17: 13-27
76. Castro M, Murillo CO, Consuegra HMI et al: Manifestaciones cardiovasculares del lupus eritematoso sistémico. Rev Colomb Cardiol Dic, 1991; 3(9): 518
77. Páez Castellanos JH, Badillo Liubinus FG: Lupus eritematoso sistémico: Análisis de 52 casos del hospital Universitario Ramón González Valencia. Med UIS, 1991; 5: 30-37
78. Molina FJ, Drenkard C, Molina J et al: Systemic lupus erythematosus in males. A study of 107 latin American patients. Medicine, 1996; 75: 1-7
79. Molina JF, Molina J, García C et al: Ethnic differences in the clinical expression of systemic lupus erythematosus: A comparative study between Africa, American and Latin American Lupus, 1997; 6: 63-67
80. Molina JF, Gutiérrez Urena S, Molina J et al: Variability of anticardioliphic populations of patients with systemic lupus erythematosus. J. Rheumatol, 1997; 24: 291-96
81. Molina JF, Gutiérrez S, Espinosa LR et al: Child hood- onset' SLE in 155 patients: A comparative study between african, americans and Latin American. Arthritis Rheum, 1995; 38(Suppl): S263
82. Molina JF, Correa P, Gómez JA et al: Polimorfismo de genes TAP1 y TAP2 en pacientes con lupus eritematoso sistémico: TAP*0201 es un marcador de susceptibilidad. Acta Med Colombiana, 2001, 26: 3-8
83. Ramírez LA, Of de la Cruz, Uribe O: Manejo del LES severo con bolos semanales de ciclofosfamida. Acta Med Colombiana, 1994; 19(S): 259
84. lck are observed in patients with SLE lupus. 1998; 7(Suppl 1): 58
85. Forero Y, Escobar J, Vernot JP: The detection of lupus anticoagulant using the kadin clotting time test: A comparative study of the different forms of analysis. Thrombosis Research, 1995; 79: 289-96
86. Zúñiga R, Ng S, Peterson MGE et al: Low-binding Alleles of Fcr Receptor types IIA and IIIA are inherited independently and are associated with systemic lupus erythematosus in hispanic patients. Arthritis Rheumatism, 2001; 44: 361-67
87. Molina JF, Anaya JM, Molina LJ: Lupus eritematoso. Manual práctico para médicos y pacientes: CIB. Medellín, Colombia, 2000
88. a edición 1998
89. Cattoggio LJ: Systemic lupus erythematosus in Argentina: An overview. Lupus, 1993; 2: 3-7
90. th Rheumatology Congress of the South Cone (Buenos Aires, October 1991): 48
91. Catoggio LJ, Sorinao E, Imamura P, Baruzzo Camera MI: Systemic lupus erythematosus: characteristics of 90 Argentine patients. Lupus, 1992; 1(Suppl.1): 123 (abstract)
92. th Argentine Congress of Rheumatology (Mar del Plata, November 1989): 37
93. th Argentine Congress of Rheumatology (Mar del Plata, November 1989): 39
94. th Rheumatology Congress of the River Plate (Rosario, October 1990): 21
95. Babini SM, Cocco JA, Babini JC et al: Atlanto axial subluxation in SLE: Further evidence of tendinous alternations. J Rheumatol, 1990; 17: 173-77
96. Carreras LO, Defreyn G, Machin SJ et al: Arterial thrombosis, intrauterine death and lupus anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet, 1981; i: 244-46
97. Forastiero RR, Martinuzzo ME, Carreras LO: Binding properties of antibodies to prothrombin and b2-glycoprotein I assayed by Elisa and dot blot. Clin Exp Immunol, 1999; 118: 480-86
98. Said PB, Martinuzzo ME, Carreras LO: Neutralization of lupus anticoagulant activity by human immunoglobulin "in vitro". Nouv Rev Fr Hematol, 1992; 34(1): 37-42
99. Kordich LC, Forastiero RR, Basilotta E et al: Natural inhibitors of blood coagulation and fibrinolysis in patients with lupus anticoagulant. Blood Coagul Fibrinolysis, 1992; 3(6): 765-71
100. Carreras LO,MacloufJ: Antiphospholipid antibodies and eicosanoids. Lupus, 1994; 3: 271-74
101. Forastiero RR, Kordich L, Basilotta E, Carrera LO: Differences in protein S and C4b-binding protein levels in different groups of patients with antiphospholipid antibodies. Blood Coagul Fibrinolysis 1994; 5(4): 609-16
102. Casellas AM, Prat A, Llera A et al: Increased superoxide production by plymorphonuclear leukocytes in systemic lupus erythematosus. Clin Exp Rheumatol, 1991; 9(5): 511-14
103. Scali JJ, Barcena P, Visentini S et al: Hyperprolactinemia, uveitis, and systemic lupus erythematosus: clinical immunological correlation. Ann NY Acad Sci, 1999; 876: 378-82
104. Bellomio B, Spinler A, Lucero E et al: Systemic lupus erythematosus: mortality and survival in Argentina. A multicenter study. Lupus, 2000; 9(5): 377-81
105. Said P, Sarano J, Manni JA, Casellas AM: Reactividad del receptor CRI en pacientes con lupus eritematoso sistémico. Medicina (Buenos Aires), 1990; 50: 21-25
106. Fassio GA, Tanca Morengo J: El lupus eritematoso diseminado considerado como enfermedad general. Gaceta Médica (Gquil), 1950; 1: 1-16
107. Tanca Marengo J: Colagenopatía en general y lupus eritematoso diseminado. Gaceta Médica (Gquil.), 1959; 14
108. Zurita L, Casing F, Moreno M: Diferente prevalencia de anticuerpos antinucleares en población normal y consumidores de drogas antituberculosas utilizando hígado de rata o células Hep_2 como sustrato. Rev Med Hospital Luis Vernaza, 1988; 1: 18-23
109. Zurita L, Moreno M: Influencia de las variedades climáticas sobre la actividad del lupus. Medicina de Hoy, 1989; 23: 9-12
110. Robles Gil J: Lesiones cardíacas en algunas enfermedades reumáticas. Arch Inst Card Mex, 1948; 18: 774-80
111. Alarcón Segovia D: Salvador Zubirán y el inicio del departamento de inmunología y reumatología. En Salvador Zubirán 1898-1998. Tomo IV. El Instituto Nacional de la Nutrición Salvador Zubirán: Pasado, presente y futuro. Colección conmemorativa. Impreso en México 1998; 249-60
112. Alarcón Segovia D, Fishbein E, Alcalá H et al: The range specificity of antinuclear antibodies in systemic lupus erythematosus. Clin Exp Immunol, 1970; 6: 557-71
113. Alarcón Segovia D, Ruiz Argüelles A, Fishbein E: Antibodies to nuclear ribonucleoprotein penetrates live in human mononuclear cells trough Fc receptors. Nature, 1978; 271: 67-69
114. Alarcón Segovia D, Ruiz Argüelles A, Llorente L: Antibody penetration into living cells. II. Anti-ribonucleoprotein IgG penetrates into T T lymphocytes causing their deletion and the abrogation of suppressor function. J Immunol, 1979; 122: 1855-62
115. Palacios R, Alarcón Segovia D, Llorente L et al: Human post-thymic precursor cells in health and disease. 1. Caracterization of the autologous rosette-forming t cells as post-thymic precursors. Immunology, 1981; 42: 127-35
116. Alcocer Varela J, Alarcón Segovia D: Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest, 1982; 69: 1388-94
117. González Amaro R, Alcocer Varela J, Alarcón Segovia D: Natural killer cell activity in dermatomyositis polymyositis. J Rheumatol, 1987; 14: 307-10
118. Granados J, Vargas-Alarcón G, Drenkard C et al: Relationship of anti-cardiolipin antibodies and antiphospholipid syndrome to HLA-DR7 in mexican patients with systemic lupys erythematosus (SLE). Lupus, 1997; 6: 57-62
119. Alarcón Segovia D, Delezé M, Oria CV et al: Antiphospholipid antibodies and the antiphospholipid syndrome in systhemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Medicine, 1989; 68: 353-65
120. Cabral AR, Amigo MC, Cabiedes J, Alarcón Segovia D: The primary antiphospholipid/cofactor syndroms: a primary variant with antibodies to b2-glicoprotein-I but no antibodies detectable in standard antiphospholipid assays. Am J Med, 1996; 101: 472-81
121. Llorente L, Richaud Patin Y, Fidor R et al: In vivo production of interleukin-10 by non-T cells in rheumatoid artritis, Sjögren s syndrome and systemic lupus erythematosus. Artritis Rheum, 1994; 37: 1647-55
122. Johansson C, Castillejo Lppeaz C et al: Association analysis with microsatellite and SNP markers does not support the involvement of Bcl-2 in systemic lupus erythematosus in Mexican and Swedish patients and their families. Genes and Immunity, 2000; 1: 380-85
123. Sánchez Guerrero J, Liang MH, Karlson EW et al: Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med, 1995; 122: 430-31
124. Fraga A, Mintz G: Splinter hemorrhage in SLE. Arthritis Rheum, 1966; 9: 648-51
125. Fraga A, Mintz G, Orozco J, Orozco JH: Sterility and fertility rates, fetal wastage and maternal morbity in systemic lupus erythematosus. J Rheumatol, 1974; 1: 293-301
126. Frajman M, Díaz Jouanen E, Alcocer Varela J et al: Effect of pregnancy on functions of circulating T cells from patients with systemic lupus erythematosus correction of T-cell suppresion and antologuus mixed lymphocytes responses. Clin Immunol Immunopathol, 1983; 29: 94-102
127. Mintz G, Fraga A: Arteritis in systemic lupus erythematosus. Arch Inter Med, 1965; 116: 55-61
128. Mintz G, Galindo LF, Fernández Diez J et al: Acute massive pulmonary hemorrhage in systemic lupus erythematosus. J Rheumatol, 1978; 5: 39-44
129. Lavalle C, Loyo E, Paniagua R et al: Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus (SLE). Arthritis Rheum, 1985; 28(Suppl.) S38
130. Lavalle C, Loyo E, Paniagua R et al: Correlation study between prolactin and androngens in male patients with systemic lupus erythematosus. J Rheumatol, 1987; 14: 268-72
131. Walker S, Jara L: Special Issue Prolactin In SLE. Lupus, 1998; 7: 371-427
132. Medina F, Ayala A, Jara L et al: Acute abdomen in systemic lupus erythematosus: The importance of early laparatomy. Am J Med, 1997; 102: 100-105
133. Herrera Esparza R, Avalos Díaz E, Moreno Rodríguez J: Biología de los anticuerpos antinucleares. Universidad Autónoma de Zacatecas. Impreso en México, 1997
134. Bori Segura G: Principales enfermedades reumáticas en México. Aspectos epidemiológicos e impacto socioeconómico. Rev Mex Reumatol, 2000; 15: 183-201
135. Castillo J, Naranjo A, Peña A et al: Mortalidad por lupus eritematoso, experiencia de 44 años Rev Mex Reumatol, 1989; 4(1): 6(No.16)
136. Amigo MC, García Torres R, Robles M et al: Renal involvement in primary antiphospholipid syndrome. J Rheumatol, 1992; 19: 1181-85
137. Amigo MC, Khamashta MA: Antiphospholipid Hughes Syndrome in systemic lupus erythematosus. Rheumatic Dis Clinics North Amer, 2000; 26: 331-48
138. Amigo MC, García Torres R: Kidney disease in antiphospholipid syndrome. In: Hughes syndrome MA, Khamashta Editor. Springer. London, 2000; 70-81
139. Miranda JM, García Torres R, Lara LJ et al: Renal biopsy of systemic lupus erythematosus: Significance of glomerular thrombosis analyces of 108 cases. Lupus, 1994; 3: 25-29
140. Abadí I, González H: Epidemiología del lupus eritematoso sistémico, la experiencia venezolana. Rev Asoc Colomb de Rheum, 1999; anuario; 17-22
141. Venezuela's network of Rheumatic Disease units grew from master plan for Geographic Coverage of Nation PANLAR. Bulletin, Vol. 7, No 2
142. Blisini Ana M, Brundula V, Paris M et al: Protein Tyrosine Kinase activity in Lymphocytes from patients with systemic lupus erythematosus. J Autoimmunity, 1998; 11: 387-93
143. Contreras CE, Rieber MS, Bianco NE, Rieber M: Human repetitive and unique sequences coexist in a large circulating DNA species found in cryoprecipitates from SLE patients. Clin Exp Immunol, 1988; 71: 73
144. Tápanes FJ, Vásquez M, Ramirez R et al: Cluster analysis of antinuclear autoantibodies in the prognosis of SLE nephropaty: are anti-extractable nuclear antibodies protective? Lupus, 2000; 9: 437-444
145. Elkon KB, Parnassa AP, Foster CL: Lupus autoantibodies target ribosomal P proteins. J Exp Med, 1985; 162: 459-67
146. Borba EF, Bonfá E: Longterm beneficial effect of chlroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy: J Rheumatol, 2001; 28: 780-85
147. Atra E, Sato EI: Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol, 1993; 11: 4877-93
148. Araújo MN, Silva NP, Andrade LE et al: C2 deficiency in blood donors and lupus patients: prevalence clinical characteristics and HLA-associations in the Brazilian population. Lupus, 1997; 6: 462-66
149. Costallat LT, Quagliato EM, Zanardi VA: Evoked potentials in the assessment of neuropsychiatric manifestations in systemic lupus erythematosus (setter). Clin Rheumatol, 1997; 16: 217-19
150. Reginato AS, Falasca GF: Connective tissue diseases in latin America 55th Annual meeting of the American college of Reumatologia Boston, 1991
151. Pons Estel B, Alarcón Segovia D: ¿Qué sabemos del lupus en Latinoamérica? Creación de una cohorte multinacional por el grupo latinoamericano del estudio del lupus Gladel. Revista Mexicana de Reumatología, 2001; 16: 105-8